TDC
GNCA

Thompson Davis & Co’s Genocea Biosciences, Inc. GNCA Stock Holding History

Thompson Davis & Co’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-63
Closed -$3K – 1242
2017
Q1 		$3K Buy
+63
New +$2.46K ﹤0.01% 1026

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Davis & Co's GNCA Position: Q2 2017 in Review

Thompson Davis & Co sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2017, closing a stake of 63 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in GNCA in Q1 2017 and held it in 1 quarter. The position peaked at $3K in Q1 2017. 61 funds tracked by Wall St. Rank hold GNCA as of Q2 2017.

  • Thompson Davis & Co reported no remaining Genocea Biosciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 63 Genocea Biosciences, Inc. shares in Q2 2017, an estimated $3K.
  • Thompson Davis & Co first reported a position in Genocea Biosciences, Inc. in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Genocea Biosciences, Inc. position peaked at $3K in Q1 2017.
  • 61 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.